Written by Jay Campbell
[Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before initiating any peptide or pharmaceutical protocol.]
Spend any amount of time on social media and you’ll see biohackers talking about the Cagrilintide and Retatrutide stack.
The idea behind this protocol is dead simple: Take extremely powerful appetite suppressants and combine them to completely eliminate any hunger or cravings.
While this stack is one of the most talked about, it’s easily one of the most misunderstood as well.
Most people start off by copying random dosage recommendations from online forums, and then wonder why they can’t get off the bathroom floor for three days.
If you’re reading this right now, I AM going to ensure this never happens to you.
So here’s what you’re going to learn when you read this article…
The RIGHT Cagri-Reta blend dosage for best results, the mechanisms powering each peptide, the potential risks to be aware of in advance, and the most common mistakes to avoid making.
Quick Takeaways
- Cagri-Reta combines Cagrilintide (an amylin analogue) with Tetatrutide (a triple incretin agonist), leading to a significant impact on satiety and energy expenditure through multiple independent pathways
- No human trials have directly studied this combination, meaning all dosing advice is extrapolated from individual compound data and clinical trials
- Slow, conservative dose escalation is non-negotiable with this stack
- The gastrointestinal side effect burden is dose-dependent, i.e. pushing too hard and too fast will only derail your results
What Is Cagri-Reta, and Why Are People Using This Stack?
Cagrilintide is a long-acting amylin analogue that activates amylin receptors — specifically calcitonin receptor and receptor activity-modifying protein (RAMP) complexes — within the area postrema and hypothalamus.
The end result is a reduction in appetite and delayed gastric emptying.
Retatrutide is a triple receptor agonist at the GLP-1, GIP, and glucagon receptors.
It leads to the simultaneous suppression of appetite, enhancement of insulin secretion, and an increase energy expenditure through glucagon-mediated thermogenesis.
So what we’re dealing with here are two of the most mechanistically advanced metabolic compounds in existence right now.
While the mechanisms are complementary and potentially synergistic, they don’t completely overlap with one another.
Retatrutide monotherapy produced up to ~24% body weight loss at 48 weeks in Phase 2 trials, which is staggering even by modern standards for pharmacological weight loss.
When you layer in an amylin analogue working through entirely different central satiety pathways, you generate an additive effect signal neither peptide on its own can replicate.
If you want the deeper dive on how Retatrutide stacks up against Tirzepatide and Semaglutide as standalone compounds, I’ve already broken that down in the linked article.
And if you’re completely new to these agents, read that article first before moving on.
The Science Behind the Cagri-Reta Synergy
Every mechanism in this stack earns its place by targeting a separate node in the metabolic control network.
GLP-1 receptor activation reduces food intake via hypothalamic POMC/CART neuron activation and delayed gastric emptying.
The glucagon receptor agonism resulting from the use of Retatrutide increases resting energy expenditure through hepatic futile cycling and thermogenesis, a mechanism confirmed in human metabolic chamber studies.
Cagrilintide operates through area postrema amylin signaling.
Critically, the combination of amylin and GLP-1 pathway co-activation also appears to reduce reward-driven eating by modulating mesolimbic dopamine signaling.
In other words: All your wants and desires for food just evaporate away (which is different from NEEDING food to survive).
A Phase 2 randomized trial of Cagrilintide in combination with Semaglutide produced roughly 15-17% weight loss.
This is markedly greater than what either compound alone can achieve, confirming incretin-amylin combination therapy is more powerful than incretin or amylin monotherapy.
The Cagri-Reta combination extrapolates this concept further by replacing Semaglutide with the far more potent Retatrutide.
To understand the differences between Cagrilintide and Semaglutide in greater detail, read the linked article for a detailed comparison.
What Most People Get Wrong About Cagri-Reta Dosing
Most people look at the highest doses used in the Phase 2 trials investigating Retatrutide, and treat them as starting points instead of endpoints reached after months of careful escalation.
What they fail to realize is both Cagrilintide and Retatrutide were studied using gradual dose-escalation protocols designed to manage gastrointestinal side effects.
Nausea, vomiting, and diarrhea are the primary factors limiting the use of both compounds.
The gastrointestinal side effect burden is dose-dependent AND additive when these compounds are combined.
This means the window between “effective” and “miserable” narrows sharply when stacking them.
There is also the glucagon receptor component to take into consideration: Glucagon receptor agonism can elevate resting heart rate and potentially one’s blood pressure levels, which creates a cardiovascular concern for select populations.
Thus, the key to success with this stack is to avoid reaching for the maximal doses from Day 1.
If you want context on how microdosing GLP-1 peptides and other appetite suppressants like Cagrilintide compares to standard approaches, , read this guide where I show you how to microdose a GLP-1 peptide properly.
Cagri-Reta Blend Dosage: An Extrapolated Framework
To be completely clear, no published human trials have directly evaluated the Cagrilintide & Retatrutide stack.
Nor does anyh peer-reviewed literature define the maximum dose of both peptides for safe use when used in combination (i.e. before the risks outweigh the benefits).
Every dosing framework for this stack is extrapolated from clinical trial data and the existing research we have on the Cagrilintide and Semaglutide stack.
So here is a rational and conservative extrapolation framework grounded in what we know…
Retatrutide Starting Range (Once-weekly subcutaneous injection):
- Start at 0.5 mg per week
- Titrate up by 0.5 to 1 mg every 4 weeks, but ONLY when it is necessary to do so
- For context: The Phase 2 trial doses ranged from 1 mg to 12 mg weekly
- The practical optimization range: 4 to 8 mg weekly for most individuals (according to what clinical trial data reveals)
Cagrilintide Starting Range (Weekly Subcutaneous):
- Start at 0.16 mg per week (matching what was done in the clinical trials)
- Titrate up by by 0.16 to 0.3 mg every 4 weeks, but ONLY when it is necessary to do so
- For context: The Phase 2 trial doses for Cagrilintide were as high as 4.5 mg weekly in combination studies
- The practical dosing range when stacked with another hunger-suppressing peptide: 0.5 to 2.4 mg weekly
The critical stacking principle to abide by: Start with Retatrutide first, and DO NOT begin Cagrilintide until Retatrutide is stable and well-tolerated at a dose you have held for at least four weeks.
What you’re effectively doing here is using two compounds with overlapping GI mechanisms.
For that reason, staggering their introduction is the smarter and safer approach
NOTE: The standalone Cagrilintide protocol in my Peptide Cheat Sheet runs at 250 mcg dosed three days per week, which lands around 750 mcg weekly total.
This would be appropriate in the context of Cagrilintide monotherapy.
But once you start stacking it with Retatrutide, the starting point is deliberately lower and dose escalations happen much less frequently.
Myth vs. Reality: Cagri-Reta Edition
| Myth | Reality |
| Higher dose = faster fat loss | Higher dose = greater gastrointestinal toxicity and dropout |
| These compounds are interchangeable | Each targets distinct receptor systems with unique risks |
| You can start both simultaneously | Simultaneous start dramatically amplifies adverse events |
| Phase 2 trial max doses are your goal dose | Trial max doses are upper bounds, not targets |
| Stopping is low risk | Weight regain after discontinuation is well-documented for this entire drug class |
I’ve also covered Cagrilintide versus Tirzepatide extensively in a separate article, and it is definitely worth reading before you decide to pursue the Cagri-Reta stack.
Cagri-Reta Safety, Risks, and Contraindications
Gastrointestinal adverse events (nausea, vomiting, diarrhea, etc.) are the most common side effects (and are also dose-dependent).
They are confirmed across all human trial data for both compounds, and will certainly be amplified with these peptides are used in combination.
GLP-1-based therapies carry an established association with increased gallbladder disease risk and rare pancreatitis (although they are extremely rate and easy to mitigate/prevent), and this observation likely extends to Retatrutide as well.
In particular, the glucagon receptor activation inherent with the use of Retatrutide may increase resting heart rate and blood pressure readings.
Therefore, you may require cardiovascular marker monitoring before, during, and after using the Cagri-Reta stack.
Cagrilintide markedly slows gastric emptying, which can alter the absorption and plasma levels of oral medications you may be taking concurrently.
Additionally, long-term safety data for Retatrutide beyond Phase 2 trials has yet to be published.
This is a frontier-breaking compound and must be treated as such.
Two more things to be mindful of:
- NEVER use this stack without baseline and ongoing labs: fasting glucose, HbA1c, lipids, liver enzymes, kidney function, and resting heart rate monitoring at minimum.
- DO NOT use this combination if you have a personal or family history of medullary thyroid carcinoma, pancreatitis, or serious cardiovascular disease without direct physician oversight.
The Cagri-Reta Durability Question No One Talks About
In the clinical studies conducted to date, weight loss achieved with multi-agonist peptide therapy depends entirely on continued treatment.
The one thing we consistently see with GLP-1 peptides is weight regain following discontinuation.
(NOTE: To learn more about WHY this happens and what you can do about it, read my newest book Metabolic Awakening With GLP-1 Peptides)
Here’s what this means for you: Any Cagri-Reta protocol you use MUST be backed by a long-term plan for health optimization.
This plan should be built around body recomposition and a full restoration of your body’s hunger and satiety pathways.
You won’t want to pursue a falling number on the scale at the expense of losing valuable muscle mass.
This is where most people fail, and it is the most important thing I can tell you about using any of these compounds.
Your Next Step: Own Your Metabolic Future
The Cagri-Reta stack is a genuinely novel approach to metabolic optimization.
It hits the amylin receptors, GLP-1 receptors, GIP receptors, and glucagon receptors simultaneously across complementary satiety and energy expenditure pathways.
The currently avaialable science supports the logic behind combination therapy at a mechanistic level, and the extrapolated dosing framework is grounded in the best available human trial data for each compound individually.
But this is groundbreaking territory, and you must approach this stack with an open and curious mind.
Start at the lowest doses possible, escalate them slowly when required, and monitor how your body responds to each peptide.
DO NOT combine Retatrutide and Cagrilintide until each compound is individually stable and tolerated.
If you want to go deeper on peptide stacking strategies, GLP-1 class compounds, and what I have learned across years as the ultimate lab rat and biohacker, get on my list so you can stay updated on the latest biohacking discoveries.
Isn’t It Time You Became Fully Optimized To Live Leaner, Longer And Stronger?
Join my #1 online membership group, Fully Optimized Health to receive guidance from me and an elite group of more than 700 male and female biohackers (who all started out just like you)
And don’t forget to check out our other premium educational content dedicated to helping you fully optimize your health:
Quantum Peptides – the A-to-Z system for anyone (newbies & pros alike) desiring to master peptide use for the first time and forever.
Quantum Testosterone – the A-to-Z system for Men & Women to learn to optimize their hormones for explosive energy, lean muscle, and timeless vitality.
The Ultimate GLP-1 Video Masterclass – how to PROPERLY utilize the world’s most powerful weight loss drugs for enhanced fat loss and overall longevity.
The Modern Woman’s Peptide Course – a must-have resource for any woman seeking to become more feminine, sexier, leaner, and healthier through the use of peptides.
Life Enhanced – Unlock the secrets to TOTAL Mind-Body-Spirit Optimization as Hunter Williams and I teach you how to live at the tip of the spear.
30 Days 2 Shredz – Reprogram Your Mind and Body for Maximum Fat Loss in Minimum Time with our Optimized Fasting Protocol
Monica Campbell’s 3 Day PMF Video Training Program – Ignite unbreakable strength, sculpt lean muscle, and conquer workouts fearlessly with my wife Monica’s 3 Day Video training course.
Positive Muscle Failure Video Training Program – Learn how to lift weights correctly for maximum muscle in minimum time while building the physique of your dreams.
See you on the inside!
